[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613595":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":175,"collaborators":25,"id":177,"slug":25,"hasResults":178,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":25,"eligibilityCriteria":182,"healthyVolunteers":178,"sex":183,"minAge":184,"maxAge":25,"enrollmentInfo":185,"targetDuration":25,"studyType":188,"phases":189,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},{"fullName":5,"class":6},"Akebia Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Praliciguat","EXPERIMENTAL","Praliciguat will be administered daily with dose escalation to a target dose during a 24-week double-blind period, followed by a 24-week open-label treatment period.",[13],"Drug: Praliciguat",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching placebo will be administered daily for 24 weeks",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Oral Tablet",[9],null,{"type":27,"name":15,"description":23,"armGroupLabels":28,"otherNames":25},"OTHER",[15],[30],{"name":5,"role":31,"phone":32,"phoneExt":25,"email":33},"CONTACT","16178446128","trials@akebia.com",[35,49,58,67,77,87,96,105,115,126,136,146,156,166],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"Investigator Site #2","RECRUITING","Chula Vista","California","91910","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.0842,32.64005,{"lat":47,"lon":46},{"facility":50,"status":37,"city":51,"state":39,"zip":52,"country":41,"countryCode":42,"cosmosGeoPoint":53,"geoPoint":57,"contacts":25},"Investigator Site #14","Los Angeles","90022",{"type":44,"coordinates":54},[55,56],-118.24368,34.05223,{"lat":56,"lon":55},{"facility":59,"status":37,"city":60,"state":39,"zip":61,"country":41,"countryCode":42,"cosmosGeoPoint":62,"geoPoint":66,"contacts":25},"Investigator Site #12","San Dimas","91773",{"type":44,"coordinates":63},[64,65],-117.80673,34.10668,{"lat":65,"lon":64},{"facility":68,"status":37,"city":69,"state":70,"zip":71,"country":41,"countryCode":42,"cosmosGeoPoint":72,"geoPoint":76,"contacts":25},"Investigator Site #13","Arvada","Colorado","80002",{"type":44,"coordinates":73},[74,75],-105.08748,39.80276,{"lat":75,"lon":74},{"facility":78,"status":37,"city":79,"state":80,"zip":81,"country":41,"countryCode":42,"cosmosGeoPoint":82,"geoPoint":86,"contacts":25},"Investigator Site #6","Coral Springs","Florida","33071",{"type":44,"coordinates":83},[84,85],-80.2706,26.27119,{"lat":85,"lon":84},{"facility":88,"status":37,"city":89,"state":80,"zip":90,"country":41,"countryCode":42,"cosmosGeoPoint":91,"geoPoint":95,"contacts":25},"Investigator Site #7","Miami","33172",{"type":44,"coordinates":92},[93,94],-80.19366,25.77427,{"lat":94,"lon":93},{"facility":97,"status":37,"city":98,"state":80,"zip":99,"country":41,"countryCode":42,"cosmosGeoPoint":100,"geoPoint":104,"contacts":25},"Investigator Site #8","Orlando","32806",{"type":44,"coordinates":101},[102,103],-81.37924,28.53834,{"lat":103,"lon":102},{"facility":106,"status":37,"city":107,"state":108,"zip":109,"country":41,"countryCode":42,"cosmosGeoPoint":110,"geoPoint":114,"contacts":25},"Investigator Site # 1","Lawrenceville","Georgia","30046",{"type":44,"coordinates":111},[112,113],-83.98796,33.95621,{"lat":113,"lon":112},{"facility":116,"status":117,"city":118,"state":119,"zip":120,"country":41,"countryCode":42,"cosmosGeoPoint":121,"geoPoint":125,"contacts":25},"Investigator Site #3","TERMINATED","Chicago","Illinois","60643",{"type":44,"coordinates":122},[123,124],-87.65005,41.85003,{"lat":124,"lon":123},{"facility":127,"status":37,"city":128,"state":129,"zip":130,"country":41,"countryCode":42,"cosmosGeoPoint":131,"geoPoint":135,"contacts":25},"Investigator Site #11","Louisville","Kentucky","40205",{"type":44,"coordinates":132},[133,134],-85.75941,38.25424,{"lat":134,"lon":133},{"facility":137,"status":37,"city":138,"state":139,"zip":140,"country":41,"countryCode":42,"cosmosGeoPoint":141,"geoPoint":145,"contacts":25},"Investigator Site #10","Pontiac","Michigan","48341",{"type":44,"coordinates":142},[143,144],-83.29105,42.63892,{"lat":144,"lon":143},{"facility":147,"status":37,"city":148,"state":149,"zip":150,"country":41,"countryCode":42,"cosmosGeoPoint":151,"geoPoint":155,"contacts":25},"Investigator Site #4","Chattanooga","Tennessee","37404",{"type":44,"coordinates":152},[153,154],-85.30968,35.04563,{"lat":154,"lon":153},{"facility":157,"status":37,"city":158,"state":159,"zip":160,"country":41,"countryCode":42,"cosmosGeoPoint":161,"geoPoint":165,"contacts":25},"Investigator Site #5","Arlington","Texas","76015",{"type":44,"coordinates":162},[163,164],-97.10807,32.73569,{"lat":164,"lon":163},{"facility":167,"status":37,"city":168,"state":159,"zip":169,"country":41,"countryCode":42,"cosmosGeoPoint":170,"geoPoint":174,"contacts":25},"Investigator Site #9","Dallas","75231",{"type":44,"coordinates":171},[172,173],-96.80667,32.78306,{"lat":173,"lon":172},{"type":176,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100613595",false,"NCT07268638","A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis","Inclusion Criteria:\n\n1. UPCR ≥1 (g\u002Fg) during screening.\n2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent.\n3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n4. Kidney biopsy within 3 years of screening consistent with FSGS or documentation of a genetic mutation in a podocyte protein associated with FSGS.\n\nExclusion Criteria:\n\n1. Collapsing FSGS in the kidney biopsy report.\n2. Sickle cell disease.\n3. HbA1c \\>8% or non-fasting blood glucose \\>180 milligram\u002Fdecilitre.\n4. Uncontrolled hypertension (≥160\u002F100 millimeters of mercury)","ALL","18 Years",{"count":186,"type":187},60,"ESTIMATED","INTERVENTIONAL",[190],"PHASE2","This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.",[193],"Focal Segmental Glomerulosclerosis",[195,196,197,198],"Glomerular Disease","Chronic Kidney Disease","Proteinuria","Urine protein-to-creatinine ratio","2026-06-03",{"date":201,"type":202},"2026-06-05","ACTUAL",{"date":204,"type":202},"2025-12-03",{"date":206,"type":187},"2028-01",{"name":5,"class":6},14]